Cannasouth Limited, a biopharmaceutical company, engages in the research, development, production, and supply of cannabis biomass and cannabinoid medicines in New Zealand.
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$0.39|
|52 Week High||NZ$0.38|
|52 Week Low||NZ$0.85|
|1 Month Change||-1.27%|
|3 Month Change||-8.24%|
|1 Year Change||-54.12%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-2.50%|
Recent News & Updates
Read This Before Buying Cannasouth Limited (NZSE:CBD) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
|CBD||NZ Pharmaceuticals||NZ Market|
Return vs Industry: CBD underperformed the NZ Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: CBD underperformed the NZ Market which returned 2.1% over the past year.
Stable Share Price: CBD is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CBD's weekly volatility (4%) has been stable over the past year.
About the Company
Cannasouth Limited, a biopharmaceutical company, engages in the research, development, production, and supply of cannabis biomass and cannabinoid medicines in New Zealand. The company was incorporated in 2018 and is based in Hamilton, New Zealand.
Cannasouth Fundamentals Summary
|CBD fundamental statistics|
Is CBD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBD income statement (TTM)|
|Cost of Revenue||NZ$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.03|
|Net Profit Margin||-2,581.27%|
How did CBD perform over the long term?See historical performance and comparison
Is Cannasouth undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CBD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CBD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CBD is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: CBD is unprofitable, so we can't compare its PE Ratio to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBD is overvalued based on its PB Ratio (4.4x) compared to the XO Pharmaceuticals industry average (3.8x).
How is Cannasouth forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannasouth has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cannasouth performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CBD is currently unprofitable.
Growing Profit Margin: CBD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CBD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CBD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.1%).
Return on Equity
High ROE: CBD has a negative Return on Equity (-33.24%), as it is currently unprofitable.
How is Cannasouth's financial position?
Financial Position Analysis
Short Term Liabilities: CBD's short term assets (NZ$4.9M) exceed its short term liabilities (NZ$447.5K).
Long Term Liabilities: CBD's short term assets (NZ$4.9M) exceed its long term liabilities (NZ$107.5K).
Debt to Equity History and Analysis
Debt Level: CBD is debt free.
Reducing Debt: CBD had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CBD has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 30.6% each year.
What is Cannasouth current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBD's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Mark John Lucas has been Managing Director of Cannasouth Limited since 2021, Executive Director since August 21, 2018 and serves as its Chief Executive Officer. He is an experienced business manager wh...
Experienced Management: CBD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: CBD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.
Cannasouth Limited's employee growth, exchange listings and data sources
- Name: Cannasouth Limited
- Ticker: CBD
- Exchange: NZSE
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$52.980m
- Shares outstanding: 135.85m
- Website: https://www.cannasouth.co.nz
- Cannasouth Limited
- 240 Victoria Street
- Level 1
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/23 06:01|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.